DR LAL PATHLABS
|
DR LAL PATHLABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 28.65 | 41.37 | 34.99 | 27.11 | 23.90 |
| CEPS(Rs) | 46.93 | 55.00 | 44.83 | 36.04 | 28.64 |
| DPS(Rs) | 12.00 | 12.00 | 20.00 | 12.00 | 6.00 |
| Book NAV/Share(Rs) | 192.88 | 173.17 | 144.61 | 119.97 | 110.08 |
| Tax Rate(%) | 29.88 | 26.25 | 24.83 | 26.70 | 33.30 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 24.29 | 26.86 | 27.59 | 25.83 | 24.40 |
| EBIT Margin(%) | 18.91 | 24.20 | 25.95 | 24.49 | 25.04 |
| Pre Tax Margin(%) | 17.05 | 22.75 | 24.94 | 23.34 | 24.97 |
| PAT Margin (%) | 11.95 | 16.78 | 18.75 | 17.11 | 16.66 |
| Cash Profit Margin (%) | 19.40 | 21.96 | 23.63 | 22.58 | 19.83 |
| Performance Ratios | |||||
| ROA(%) | 10.36 | 17.77 | 19.87 | 18.81 | 20.38 |
| ROE(%) | 15.80 | 26.45 | 26.89 | 23.74 | 23.76 |
| ROCE(%) | 20.34 | 32.67 | 36.03 | 32.94 | 34.78 |
| Asset Turnover(x) | 0.87 | 1.06 | 1.06 | 1.10 | 1.22 |
| Sales/Fixed Asset(x) | 1.14 | 1.73 | 2.51 | 3.04 | 4.26 |
| Working Capital/Sales(x) | 4.01 | 5.56 | 1.82 | 2.00 | 1.78 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.88 | 0.58 | 0.40 | 0.33 | 0.23 |
| Receivable days | 14.14 | 13.30 | 13.63 | 14.35 | 14.31 |
| Inventory Days | 7.81 | 8.31 | 11.49 | 11.73 | 8.47 |
| Payable days | 123.86 | 105.92 | 120.30 | 120.69 | 101.04 |
| Valuation Parameters | |||||
| PER(x) | 63.80 | 63.02 | 77.38 | 51.69 | 44.12 |
| PCE(x) | 38.95 | 47.40 | 60.39 | 38.88 | 36.82 |
| Price/Book(x) | 9.48 | 15.06 | 18.72 | 11.68 | 9.58 |
| Yield(%) | 0.66 | 0.46 | 0.74 | 0.86 | 0.57 |
| EV/Net Sales(x) | 7.34 | 10.28 | 13.68 | 8.35 | 6.90 |
| EV/Core EBITDA(x) | 27.86 | 34.99 | 44.38 | 27.87 | 24.43 |
| EV/EBIT(x) | 38.83 | 42.48 | 52.73 | 34.10 | 27.53 |
| EV/CE(x) | 6.32 | 9.29 | 13.25 | 8.22 | 7.76 |
| M Cap / Sales | 7.56 | 10.41 | 14.27 | 8.78 | 7.30 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -3.38 | 32.01 | 18.86 | 10.55 | 13.86 |
| Core EBITDA Growth(%) | -13.32 | 25.77 | 22.32 | 17.38 | 15.04 |
| EBIT Growth(%) | -24.51 | 23.09 | 25.96 | 8.11 | 14.96 |
| PAT Growth(%) | -31.18 | 18.15 | 30.27 | 13.53 | 16.72 |
| EPS Growth(%) | -30.75 | 18.25 | 29.07 | 13.43 | 16.65 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.15 | 0.24 | - | - | - |
| Current Ratio(x) | 2.07 | 1.75 | 4.18 | 3.93 | 5.88 |
| Quick Ratio(x) | 2.00 | 1.65 | 4.02 | 3.68 | 5.68 |
| Interest Cover(x) | 10.16 | 16.74 | 25.65 | 21.28 | 359.22 |
| Total Debt/Mcap(x) | 0.02 | 0.02 | - | - | - |
Compare Financial Ratios of peers of DR LAL PATHLABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DR LAL PATHLABS | ₹18,422.6 Cr | 12.9% | -7.3% | 19.6% | Stock Analytics | |
| APOLLO HOSPITALS ENTERPRISE | ₹88,715.9 Cr | 3.4% | -6.6% | 49% | Stock Analytics | |
| MAX HEALTHCARE INSTITUTE | ₹75,026.8 Cr | 5.7% | -8.7% | 59.1% | Stock Analytics | |
| GLOBAL HEALTH | ₹37,656.8 Cr | 6.7% | -13.1% | 164.4% | Stock Analytics | |
| FORTIS HEALTHCARE | ₹32,512.3 Cr | 2.6% | -6.4% | 59.4% | Stock Analytics | |
| NARAYANA HRUDAYALAYA | ₹25,374.5 Cr | 2% | -9.6% | 59.5% | Stock Analytics | |
DR LAL PATHLABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DR LAL PATHLABS | 12.9% |
-7.3% |
19.6% |
| SENSEX | -2.6% |
-0% |
21% |
You may also like the below Video Courses
